Cardiff Oncology (CRDF) Reports Q2 Loss, Lags Revenue Estimates

Company Performance - Cardiff Oncology reported a quarterly loss of $0.21 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.19, representing an earnings surprise of -10.53% [1] - The company posted revenues of $0.12 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 19.33%, compared to revenues of $0.16 million a year ago [2] - Over the last four quarters, Cardiff Oncology has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Movement and Outlook - Cardiff Oncology shares have declined approximately 14.1% since the beginning of the year, while the S&P 500 has gained 8.6% [3] - The company's earnings outlook will be crucial for future stock performance, with current consensus EPS estimates at -$0.21 on $0.15 million in revenues for the coming quarter and -$0.77 on $0.57 million in revenues for the current fiscal year [4][7] Industry Context - The Medical - Biomedical and Genetics industry, to which Cardiff Oncology belongs, is currently in the top 38% of over 250 Zacks industries, indicating a favorable industry outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Cardiff Oncology's stock performance [5]